Tirzepatide for Weight Loss: Medicine Explained

Tirzepatide is a dual GIP and GLP-1 receptor agonist — meaning it activates two incretin pathways instead of one. This dual action can provide stronger metabolic signaling for certain patients in supervised weight management programs, compared to single-pathway GLP-1 medicines alone.

How Dual Agonism Works

• GLP-1 receptor activation reduces appetite and slows digestion
• GIP receptor activation adds complementary metabolic and insulin-support effects
• Combined signaling may improve outcomes for patients who plateau on GLP-1-only therapy
• Requires the same structured titration and monitoring as other injectable medicines

Available Master Pharm Formats

• Tirzepatide 45mg / 3ml vial — multi-dose clinical supply
• Tirzepatide pre-filled pen — streamlined dispensing
• Tirzepatide sublingual drops — oral alternative under clinic protocol